Design Therapeutics, Inc. (DSGN)

NASDAQ: DSGN · IEX Real-Time Price · USD
2.960
+0.080 (2.78%)
Feb 27, 2024, 4:00 PM EST - Market closed
2.78%
Market Cap 165.77M
Revenue (ttm) n/a
Net Income (ttm) -72.36M
Shares Out 56.00M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 359,930
Open 2.920
Previous Close 2.880
Day's Range 2.860 - 2.990
52-Week Range 1.940 - 8.470
Beta 1.65
Analysts Hold
Price Target 5.33 (+80.07%)
Earnings Date Mar 12, 2024

About DSGN

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromus... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 57
Stock Exchange NASDAQ
Ticker Symbol DSGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for DSGN stock is "Hold." The 12-month stock price forecast is $5.33, which is an increase of 80.07% from the latest price.

Price Target
$5.33
(80.07% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Re...

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN

NEW YORK , Oct. 9, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such investors are advised...

5 months ago - PRNewsWire

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Shares of Design Therapeutics Inc. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stage trial of a treatment for Friedreich ataxia, a ge...

7 months ago - Market Watch

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle

7 months ago - GlobeNewsWire

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composit...

7 months ago - GlobeNewsWire

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, tod...

9 months ago - GlobeNewsWire

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Expected in the Third Quarter of 2023

10 months ago - GlobeNewsWire

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2...

11 months ago - GlobeNewsWire

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Ongoing with Data Expected Mid-Year

1 year ago - GlobeNewsWire

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

CARLSBAD, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, to...

1 year ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Design Therapeutics, Inc. - DSGN

New York, New York--(Newsfile Corp. - January 7, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such inve...

1 year ago - Newsfile Corp

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia

1 year ago - GlobeNewsWire

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022

1 year ago - GlobeNewsWire

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022 Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-...

1 year ago - GlobeNewsWire

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t...

1 year ago - GlobeNewsWire

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022

1 year ago - GlobeNewsWire

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

CARLSBAD, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, to...

1 year ago - GlobeNewsWire

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, to...

1 year ago - GlobeNewsWire

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Clinical Execution of Lead GeneTAC™ Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of Friedreich Ataxia

1 year ago - GlobeNewsWire

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Phase 1 Trial of DT-216, a Novel FA GeneTAC™  Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon

2 years ago - GlobeNewsWire

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

Treatment with GeneTAC™ Small Molecules Reduced Nuclear Foci and Restored Normal Splicing In Vitro, Supporting Further Development Treatment with GeneTAC™ Small Molecules Reduced Nuclear Foci and Rest...

2 years ago - GlobeNewsWire

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon

2 years ago - GlobeNewsWire

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João...

2 years ago - GlobeNewsWire

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that Jae...

2 years ago - GlobeNewsWire